Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment. To do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and/or skin swabs.

NCT Number	NCT05270733
Lead Sponsor	University Hospitals Cleveland Medical Center Collaborators: LEO Foundation, Case Western Reserve University
Conditions	Psoriasis
Enrollment	56 participants
Start Date	2022-11-10
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-02